SurvivX is an early-stage biotech company developing a pharmaceutical product for the treatment of sepsis.
Sepsis is one of the largest causes of admissions to the intensive care units in hospitals (11% in high income countries). The chance to die from sepsis after admission to the ICU is 30 to 40 procent in Dutch hospitals – worldwide, these figures are even higher. The pressure of sepsis on the healthcare system is strong, the disease is associated with very long hospitalizations, intensive care and remaining physical and mental consequences for survivors.
We have a revolutionary new approach towards improving the outcome of sepsis. We are developing a unique immune enhancer, which we call SUR-101, and is intended as a novel immune stimulating therapeutic in sepsis patients with signs of immune suppression.
How to become part of our journey
We are a young company, and we are full of ambitions. Here is how you can contribute: